(PRWEB) February 22, 2013
Research and Markets has announced the addition of the "Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma" report to their offering.
Over the next five years, we will witness surge in approval of new drugs that would deliver a major improvement in the standard of care. Therapy areas - Oncology, Diabetes, Ophthalmology HCV, Atrial Fibrillation, Multiple Sclerosis, Dyslipidemia, Alzheimer's and Melanoma are few select areas where newer therapies that are safer and more efficacious will reach the market. Many of these innovations promise a paradigm shift in the standard of care.
The year 2012 has marked the beginning of this trend as many new blockbuster drugs were approved and we also witnessed promising proof of concept data on many of the potential path breaking innovation. There are also major outcome clinical trials that will deliver data over the next few years and if positive, we will see the change in fortunes of many existing drugs that are on the market.
In the near term as well the sector continues to remain attractive, as cost containment initiatives, restructuring/deconsolidation, share repurchase program, M&A, emerging market growth potential and dividend policy continue to be encouraging. Over the next few years, the growth of the industry would be shaped up by a battle between fundamental growth drivers (Value added innovation) versus regulatory pressures to contain costs.
Global Biopharmaceutical Outlook 2013-Global Pharma, released by MP Advisors provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry.
Some Key Topics Covered - Please click here for a full list
- Value Based Pricing- Strength of Innovation Vs Fiscal Pressures
- Europe - Regulatory Pressures and Increasing Pro Generic Stance
- Will US fall to Pricing Pressures?
- Emerging Markets and their importance in Growth of Large Cap Pharma
- Global Pharma -Drugs Losing Patent Protection By 2017
- Novartis: Back on a Growth Trajectory
- Novo Nordisk: Hemophilia Franchise and Thrice Weekly Degludec – The Future Drivers
- Pfizer: M&A Only Can Drive Further Upside In The Near Term
Companies Mentioned in this report include AstraZeneca, Bristol Myers-Squibb, Pfizer, Merck, Novartis, Novo Nordisk, GlaxoSmithKline, Roche, Sanofi and Eli-Lilly.
For more information visit http://www.researchandmarkets.com/research/st6sdr/global
Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716